| Literature DB >> 35425842 |
Mei Yang1, Zhanting Yang1,2, Yongfang Li1, Shanshan Su3, Zhanqiang Li1,2, Dianxiang Lu1,2.
Abstract
Objective: This study was aimed at investigating the potential mechanism of Grubthobrildkr (GTB) on systemic hypoxia-induced gastric ulcers in rats and at detecting the chemical profile of GTB.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35425842 PMCID: PMC9005313 DOI: 10.1155/2022/4803956
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Effect of GTB on mean gross lesion index and inhibition rate of gastric mucosal ulcer in rat under acute systemic hypoxia for 6 days. The five groups including hypoxia (H), H+omeprazole, H+GTB 0.25 g/kg, H+GTB 0.5 g/kg, and H+GTB 1 g/kg were induced by systemic hypoxia (rats exposed to hypoxia in hypobaric chamber, equal to the parameter in altitude 5000 m) for 6 days. Each value represents the mean ± S.D. value of eight animals. ∗P < 0.05 vs. hypoxia group.
Figure 2Effect of GTB on volume (a) and pH (b) of gastric juice in rat under acute systemic hypoxia for 6 days (, n = 12). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The volume and pH of the gastric juice were detected. Results are expressed as mean ± S.D.#P < 0.05 as compared with the control group; ∗P < 0.05 as compared with the hypoxia group.
Figure 3Effect of GTB on gastrin (a), endothelin-1 (b), and motilin (c) level in blood in rat under systemic hypoxia for 6 days (, n = 12). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The level of gastrin, endothelin-1, and motilin in blood in rat was detected by enzyme-linked immunosorbent assay (ELISA). Results were expressed as mean ± S.D.#P < 0.05 as compared with the control group; ∗P < 0.05 as compared with the hypoxia group.
Figure 4Effect of GTB on phospholipase A2 (PLA2) level in blood (a) and gastric mucosa (b) in rat under systemic hypoxia for 6 days (, n = 12). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The level of phospholipase A2 (PLA2) in blood and gastric mucosa in rat was detected by enzyme-linked immunosorbent assay (ELISA). Results were expressed as mean ± S.D.#P < 0.05 as compared with the control group; ∗P < 0.05 as compared with the hypoxia group.
Figure 5Effect of GTB on prostaglandin E2 (PGE2) level in blood (a) and gastric mucosa (b) in rat under systemic hypoxia for 6 days (, n = 12). Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTB-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. The level of PGE2 in blood and gastric mucosa in rat was detected by enzyme-linked immunosorbent assay (ELISA). Results were expressed as mean ± S.D.#P < 0.05 as compared with the control group; ∗P < 0.05 as compared with the hypoxia group.
Figure 6Effect of GTB on hydrogen potassium ATPase (H+-K+-ATPase) protein expression in gastric mucosal tissue detected by Western blotting. Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. GAPDH protein expression was used as a control. Relative expression levels of H+-K+-ATPase. Data were expressed as mean ± S.D. of three identical experiments. #P < 0.05 as compared with the control group; ∗P < 0.05 as compared with the hypoxia group.
Figure 7Effect of GTB on cyclooxygenase-1 (COX-1) protein expression in gastric mucosal tissue in rat detected by Western blotting. Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. GAPDH protein expression was used as a control. Relative expression levels of COX-1. Data are mean ± S.D. of three identical experiments. #P < 0.05 as compared with the control group; ∗P < 0.05 as compared with the hypoxia group.
Figure 8Effect of GTB on cyclooxygenase-2 (COX-2) protein expression in gastric mucosal tissue in rat detected by Western blotting. Rats were exposed to hypoxia (in hypobaric chamber, equal to the parameter in altitude 5000 m), hypoxia (H)+omeprazole treatment (7 mg/kg/d), and hypoxia (H)+GTBs-treatment (0.25, 0.5, and 1.0 mg/kg/d) for 6 days. GAPDH protein expression was used as a control. Relative expression levels of COX-2. Data are mean ± S.D. of three identical experiments. #P < 0.05 as compared with the control group; ∗P < 0.05 as compared with the hypoxia group.
Figure 9UHPLC-Q-exactive hybrid quadrupole-orbitrap mass analysis chromatogram of aqueous extract of GTB. (a) Total ion chromatograms (TIC) chromatogram in positive electrospray ionization (ESI) mode. (b) TIC chromatogram in negative ESI mode. Peaks 1–44 represent stachydrine, adenine, guanine, cinnamic acid, isovanillin, esculetin, 7,8-dihydroxycoumarin, anisic aldehyde, paeonol, corydine, boldine, phellodendrine, 7-hydroxycoumarin, bicuculline, protopine, berberrubine, baicalin, dihydropalmatine, allocryptopine, berberine, dehydroglaucine, dihydrosanguinarine, curcumol, micheliolide, diosmetin, andrographolide, isosteviol, carnosol, glabrolide, cafestol, quillaic acid, clareolide, 6-gingerol, piperine, atractylenolide II, isoalantolactone, dehydrocostus lactone, lindenenol, abietic acid, deoxyandrographolide, steviol, kahweol, nonivamide, and alpha-linolenic acid.
Compounds identified in aqueous extract of GTB by UHPLC-Q-exactive hybrid quadrupole-orbitrap mass analysis.
| No. | tR (min) | MS ( | MS/MS ( | Molecular formula | Identification | ||
|---|---|---|---|---|---|---|---|
| Observed mass (Da) | Calculated mass (Da) | Error (ppm) | |||||
| 1 | 0.64 | 144.10191 [M+H]+ | 144.10175 | -1.11 | 103.13138, 84.08134, 98.09679, and 70.06587 | C7H13NO2 | Stachydrine |
| 2 | 0.73 | 136.06177 [M+H]+ | 136.06165 | -0.88 | 109.05100 | C5H5N5 | Adenine |
| 3 | 0.86 | 152.05669 [M+H]+ | 152.05661 | -0.53 | 110.03516, 135.02991, 128.04541, and 107.04948 | C5H5N5O | Guanine |
| 4 | 2.5 | 149.05971 [M+H]+ | 149.05962 | -0.60 | 121.06486, 118.04142, 131.04907, and 103.05457 | C9H8O2 | Cinnamic acid |
| 5 | 3.82 | 153.05462 [M+H]+ | 153.05449 | -0.85 | 125.05972, 93.07038, 111.96861, and 129.97884 | C8H8O3 | Isovanillin |
| 6 | 4.39 | 179.03389 [M+H]+ | 179.03365 | -1.34 | 151.03896,114.94835, 123.04412, and 133.02834 | C9H6O4 | Esculetin |
| 7 | 4.4 | 179.03389 [M+H]+ | 179.03365 | -1.34 | 123.04412, 117.03340 | C9H6O4 | 7,8-Dihydroxycoumarin |
| 8 | 5.36 | 137.05971 [M+H]+ | 137.05962 | -0.66 | 109.06524 | C8H8O2 | Anisic aldehyde |
| 9 | 6.63 | 167.07027 [M+H]+ | 167.07007 | -1.20 | 125.05970, 121.10149, 84.96030, and 110.03656 | C9H10O3 | Paeonol |
| 10 | 7.26 | 342.16998 [M+H]+ | 342.16922 | -2.22 | 297.11166, 265.08533, and 237.09053 | C20H23NO4 | Magnoflorine |
| 11 | 7.92 | 328.15433 [M+H]+ | 328.15372 | -1.86 | 237.09117, 297.11176, 178.08595, and 163.06247 | C19H21NO4 | Boldine |
| 12 | 8.28 | 342.16998 M+ | 342.16934 | -1.87 | 192.10162, 177.07811 | C20H24NO4 | Phellodendrine |
| 13 | 8.84 | 163.03897 [M+H]+ | 163.03870 | -1.66 | 107.04945 | C9H6O3 | 7-Hydroxycoumarin |
| 14 | 9.15 | 368.11286 [M+H]+ | 368.11218 | -1.85 | 307.05954, 277.04910, 249.05411, and 190.08597 | C20H17NO6 | (+)Bicuculline |
| 15 | 9.73 | 354.13360 [M+H]+ | 354.13281 | -2.23 | 188.07033, 275.06979, 188.07033, and 149.05962 | C20H19NO5 | Protopine |
| 16 | 9.86 | 322.10738 [M+H]+ | 322.10690 | -1.49 | 279.08868, 234.09065, 307.08350, and 250.08571 | C19H15NO4 | Berberrubine |
| 17 | 9.95 | 447.09219 [M+H]+ | 447.09177 | -0.94 | — | C21H18O11 | Baicalin |
| 18 | 10.39 | 354.16998 [M+H]+ | 354.13232 | -106.33 | 336.12201, 320.09183, 190.08597, and 275.06976 | C21H23NO4 | Dihydropalmatine |
| 19 | 10.60 | 370.16490 [M+H]+ | 370.16428 | -1.67 | 290.09338, 188.07036 | C21H23NO5 | Allocryptopine |
| 20 | 10.96 | 336.12303 M+ | 336.12247 | -1.67 | 278.08099, 292.09616 | C20H18NO4 | Berberine |
| 21 | 11.17 | 354.16998 [M+H]+ | 354.16943 | -1.55 | 338.13928, 306.12180, 192.10165, and 165.09084 | C21H23NO4 | Dehydroglaucine |
| 22 | 12.22 | 334.10738 [M+H]+ | 334.10669 | -2.07 | 319.08340, 261.07614, 302.07990, and 290.08054 | C20H15NO4 | Dihydrosanguinarine |
| 23 | 12.78 | 237.18491 [M+H]+ | 237.18472 | -0.80 | 196.01671, 182.98506 | C15H24O2 | Curcumol |
| 24 | 14.00 | 249.14852 [M+H]+ | 249.14781 | -2.85 | 231.13780, 185.13234, 135.08034, and 119.08567 | C15H20O3 | Micheliolide |
| 25 | 14.24 | 301.07066 [M+H]+ | 301.07016 | -1.66 | 286.04666, 147.11650, 258.05185, and 229.04871 | C16H12O6 | Diosmetin |
| 26 | 14.72 | 351.2166 [M+H]− | 351.21790 | 3.70 | 333.20121, 305.21259, 289.21765, and 183.10057 | C20H30O5 | Andrographolide |
| 27 | 15.52 | 319.22677 [M+H]+ | 319.22577 | -3.13 | 273.22053, 255.21010, 301.21591, and 147.11681 | C20H30O3 | Isosteviol |
| 28 | 16.00 | 331.19039 [M+H]+ | 331.18976 | -1.90 | 285.18408, 215.10663, 203.10638, and 171.08023 | C20H26O4 | Carnosol |
| 29 | 16.12 | 469.33075 [M+H]+ | 469.33124 | 1.04 | 95.08595, 299.20111, 119.08565, and 405.31430 | C30H44O4 | Glabrolide |
| 30 | 16.14 | 317.21112 [M+H]+ | 317.21118 | 0.19 | 281.19016, 131.08543, 299.20016, and 271.20538 | C20H28O3 | Cafestol |
| 31 | 16.16 | 487.34024 [M+H]+ | 487.34180 | 3.20 | 451.32074, 187.14790, 119.08562, and 201.16367 | C30H46O5 | Quillaic acid |
| 32 | 16.66 | 251.20056 [M+H]+ | 251.20020 | -1.43 | 1187.14793, 215.17897, 233.18958, and 95.08595 | C16H26O2 | Clareolide |
| 33 | 18.00 | 293.17583 [M+H]− | 293.17603 | 0.68 | 236.10522, 177.09090, 221.15428, and 249.18590 | C17H26O4 | 6-Gingerol |
| 34 | 19.08 | 286.14377 [M+H]+ | 286.14334 | -1.50 | 201.05440, 143.04912,135.04396, and 115.05444 | C17H19NO3 | Piperine |
| 35 | 20.38 | 233.15361 [M+H]+ | 233.15335 | -1.12 | 187.14793, 145.10107 | C15H20O2 | Atractylenolide II |
| 36 | 20.28 | 233.15361 [M+H]+ | 233.15334 | -1.16 | 187.14796, 159.11668, 215.14293, and 145.10109 | C15H20O2 | Isoalantolactone |
| 37 | 20.84 | 231.13796 [M+H]+ | 231.13757 | -1.69 | 185.13225, 143.08539, 195.11664, and 157.10092 | C15H18O2 | Dehydrocostus lactone |
| 38 | 20.84 | 231.13796 [M+H]+ | 231.13757 | -1.69 | 105.07019, 98.03719, 119.08562, and 131.08542 | C15H18O2 | Lindenenol |
| 39 | 21.08 | 303.23186 [M+H]+ | 303.23138 | -1.58 | 257.22589, 123.12687, and 147.11668 | C20H30O2 | Abietic acid |
| 40 | 21.22 | 335.22169 [M+H]+ | 335.22305 | 4.06 | 289.21722, 129.90915, and 275.20213 | C20H30O4 | Deoxyandrographolide |
| 41 | 21.27 | 319.22677 [M+H]+ | 319.22650 | -0.85 | 227.14243, 273.22098, 255.21030, and 161.13228 | C20H30O3 | Steviol |
| 42 | 22.42 | 315.19547 [M+H]+ | 315.19513 | -1.08 | 303.97168, 145.06465, 187.11153, and 269.18951 | C20H26O3 | Kahweol |
| 43 | 23.26 | 294.20637 [M+H]+ | 294.20685 | 1.63 | 161.09586, 137.05959, 179.10640, and 203.10635 | C17H27NO3 | Nonivamide |
| 44 | 29.25 | 279.23186 [M+H]+ | 279.23145 | -1.47 | 95.08595, 81.07049, and 67.05501 | C18H30O2 | Alpha-linolenic acid |
tR: retention time.